Skip to content
★ Sign in to follow
TA

Tamara A. Seymour

Board Director
Director
Total declarations
20
Companies
3
▲ Purchases (2 ops.)
€3,278
▼ Sales (1 ops.)
€64

Latest filing published 21 Mar 2023 for ZEVRA THERAPEUTICS, INC., €2,358.

Filing timeline

BuySale
Tamara A. Seymour

Insider track record

Disclosed buys
2
Disclosed sells
1
Signal history

Closed purchases

Market purchases
2
Positive at T+90
100%
Median T+90
+20.4%

Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Tamara A. Seymour: trading record in brief

Filings by Tamara A. Seymour span 3 companies, the busiest being MMRGlobal, Inc., Viridian Therapeutics, Inc.\DE and Zevra Therapeutics, Inc. Over a trading history stretching from 7 February 2005 to 17 March 2023, the count stands at 20 filings.

Market trades split into 2 purchases (€3,278) and 1 sale (€64). Purchases outweigh sales by €3,215. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 4 share grants and 6 option exercises. 2023 to date brings 1 purchase and no sales.

The latest filing, published on 21 March 2023, reports an open-market purchase of €2,358 in Zevra Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Tamara A. Seymour

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations20 total

20 of 20 declarations